KALA BIO

KALA BIO is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat rare and serious eye diseases. The company is a leader in the emerging field of mesenchymal stem cell secretome (MSC-S) therapy, a cell-free approach that utilizes the regenerative potential of human MSC-S to drive therapeutic benefit. KALA BIO's proprietary MSC-S platform is being used to develop therapies for both rare ocular surface diseases, such as persistent corneal epithelial defect (PCED), and rare inherited retinal diseases (IRDs), such as retinitis pigmentosa and Stargardt disease.

KALA BIO has a history of innovation in ophthalmic therapy, having previously developed and secured FDA approval for two ophthalmic products: EYSUVIS® and INVELTYS®. In 2022, the company completed the sale of its commercial products to Alcon Inc., enabling it to focus on its biologics pipeline. KALA BIO is committed to improving vision and changing lives for patients with rare, sight-threatening diseases.

KALA BIO is a clinical-stage biopharmaceutical company dedicated to solving rare and serious eye diseases through the development of innovative therapies. They are leaders in the field of mesenchymal stem cell secretome (MSC-S) therapy and utilize their proprietary platform to create treatments that promote regenerative healing in rare ocular surface and retinal diseases. Their ultimate goal is to preserve vision and change the lives of patients suffering from these debilitating conditions.

KALA BIO fosters a culture of innovation and dedication, driven by a shared mission to improve vision and change lives. The company prioritizes advanced scientific research and development of groundbreaking therapies to address rare and serious eye diseases. This mission-driven environment encourages collaboration, perseverance, and a deep commitment to making a real difference in the lives of patients.